کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3341734 | 1214237 | 2013 | 6 صفحه PDF | دانلود رایگان |
In APS vascular patients, thrombotic recurrences are more frequent than in non-APS thrombotic patients. To better define this clinical setting, a systematic review of the literature after 1999 was performed: 8 cohort studies (including the recent APS Piedmont Cohort) and 6 intervention studies were selected and evaluated. Thrombotic recurrences, bleeding events, therapeutic strategies, antiphospholipid (aPL) profile, inherited and acquired risk factors (when present) were calculated and compared. Emerging risk factors for thrombotic recurrences include withdrawal of oral anticoagulant therapy (OAT), high intensity OAT (INR range 3–4), aPL profile (triple positivity, Miyakis types 1 and 2a profiles) and association with inherited or acquired pro-thrombotic risk factors. Moreover, there are evidences that high risk (mainly for aPL profile) APS vascular patients have a high recurrence rate in spite of correct OAT treatment. Clinical trials in this clinical setting are needed.
► A review of the literature, concerning studies on APS vascular patients, was performed.
► The recent APS Piedmont Cohort was evaluated.
► Risk factors for recurrences and bleedings were calculated and compared.
► Emerging risk factors for recurrences were either OAT withdrawal or high intensity OAT.
► aPL profile, inherited or acquired pro-thrombotic are also risk factors for thrombotic recurrences.
Journal: Autoimmunity Reviews - Volume 12, Issue 8, June 2013, Pages 826–831